Copy to clipboard 
Episurf reported 3Q19 revenue of SEK 1.1MM (USD $0.1MM), +13.4% vs. 3Q18.
- Gross order intake for the quarter increased 21% year over year, and 51% for the nine-month period ending September 30, 2019
- Per leadership, around 80% of Episealer orders originate in Germany
- Orders for the Episealer knee implant increased 60% vs. prior year, with 56 orders in the quarter
- Within the quarter, Episurf achieved a milestone of 600 implantations to date and gained approval to sell the Episealer knee implant in Italy
- The company experienced increased costs in the quarter due to work on its Investigational Device Exemption study in the U.S., amounting to SEK 5MM (USD $.5MM)
- Episurf expects CE Mark approval for the Episealer Talus ankle implant before the end of 2019
- In July 2019, the company entered into a Letter of Intent with a US-based orthopedic company for use of its AI-based Epioscopy imaging technology and now has a trial agreement in place to jointly explore opportunities for further commercial collaboration
- ORTHOWORLD projects Episurf 2019 full year revenue of SEK 4.8MM (USD $.5MM), +17% vs. 2018
“We are only scratching the surface of our addressable market, and we look forward to further market penetration. The key to achieving this is to have more clinical evidence published, which will lead to animproved operating environment, meaning that factors such as hospital approvals, surgeon confidence, reimbursement and patient awareness are improved.” – Episurf CEO Pål Ryfors
ORTHOWORLD estimates segment sales and growth on an as-reported basis ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement, Knees | $0.1 | $0.1 | $0.0 | 13.4% |
| 9mo 19 | 9mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement, Knees | $0.4 | $0.3 | $0.1 | 20.8% |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Episurf reported 3Q19 revenue of SEK 1.1MM (USD $0.1MM), +13.4% vs. 3Q18.
Gross order intake for the quarter increased 21% year over year, and 51% for the nine-month period ending September 30, 2019
Per leadership, around 80% of Episealer orders originate in Germany
Orders for the Episealer knee implant increased 60% vs. prior...
Episurf reported 3Q19 revenue of SEK 1.1MM (USD $0.1MM), +13.4% vs. 3Q18.
- Gross order intake for the quarter increased 21% year over year, and 51% for the nine-month period ending September 30, 2019
- Per leadership, around 80% of Episealer orders originate in Germany
- Orders for the Episealer knee implant increased 60% vs. prior year, with 56 orders in the quarter
- Within the quarter, Episurf achieved a milestone of 600 implantations to date and gained approval to sell the Episealer knee implant in Italy
- The company experienced increased costs in the quarter due to work on its Investigational Device Exemption study in the U.S., amounting to SEK 5MM (USD $.5MM)
- Episurf expects CE Mark approval for the Episealer Talus ankle implant before the end of 2019
- In July 2019, the company entered into a Letter of Intent with a US-based orthopedic company for use of its AI-based Epioscopy imaging technology and now has a trial agreement in place to jointly explore opportunities for further commercial collaboration
- ORTHOWORLD projects Episurf 2019 full year revenue of SEK 4.8MM (USD $.5MM), +17% vs. 2018
“We are only scratching the surface of our addressable market, and we look forward to further market penetration. The key to achieving this is to have more clinical evidence published, which will lead to animproved operating environment, meaning that factors such as hospital approvals, surgeon confidence, reimbursement and patient awareness are improved.” – Episurf CEO Pål Ryfors
ORTHOWORLD estimates segment sales and growth on an as-reported basis ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement, Knees | $0.1 | $0.1 | $0.0 | 13.4% |
| 9mo 19 | 9mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement, Knees | $0.4 | $0.3 | $0.1 | 20.8% |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
